Clinical trial
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
NCT00386685 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00386685 |
|---|---|
| Title | XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer |
| Official title | Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | larotaxel (XRP9881), trastuzumab |
| Enrollment | 51 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Jan 1, 2011 |
| First posted | Oct 11, 2006 |
| Last update posted | Apr 12, 2011 |
| Countries | Belgium, France, Sweden, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: